Search

INTRODUCTION AND OBJECTIVE:There is debate about the effectiveness and toxicity of pelvic lymph node (PLN) irradiation when used for disease recurrence following radical prostatectomy. This study c...

INTRODUCTION AND OBJECTIVE:No direct comparison has been made between England and the US with respect to the diagnosis and treatment of men with prostate cancer over one contemporary time period. W...

Multiparametric magnetic resonance imaging can be used to guide prostate biopsy by targeting biopsies to areas in the prostate at high risk for cancer. We compared the detection of clinically significant and insignificant cancer by transperineal magnetic resonance imaging targeted biopsy and transperineal template guided prostate biopsy.A total of 182 men with a lesion suspicious for cancer on multiparametric magnetic resonance imaging underwent transperineal magnetic resonance imaging targeted biopsy using a cognitive registration technique, followed by systematic transperineal template guided prostate biopsy. The primary outcome was the detection rate of clinically significant prostate cancer. Clinical significance was defined using maximum cancer core length 4 mm or greater and/or Gleason grade 3 + 4 or greater (University College London definition 2). We secondarily evaluated other commonly used thresholds of clinically significant disease, including maximum cancer core length 6 mm or greater and/or Gleason grade 4 + 3 or greater, maximum cancer core length 3 mm or greater and/or Gleason grade 3 + 4 or greater, and maximum cancer core length 2 or greater mm and/or Gleason grade 3 + 4 or greater. Strategies were statistically compared with the McNemar test.Mean ± SD patient age was 63.3 ± 7.2 years. Median prostate specific antigen was 6.7 ng/ml (IQR 4.7-10.0). Clinically significant cancer was detected by magnetic resonance imaging targeted biopsy and template guided prostate biopsy in 103 (57%) and 113 of the 182 men (62%) (p = 0.174), and clinically insignificant cancer was detected in 17 (9.3%) and 31 (17.0%), respectively (p = 0.024).Prostate biopsy targeted to suspicious lesions on multiparametric magnetic resonance imaging has encouraging rates of detection of clinically significant cancer while also decreasing the detection rate of clinically insignificant cancer. This is achieved with fewer biopsy cores than for systematic template guided biopsy. Further prospective, multicenter, comparative trials of the performance of targeting strategies are needed to consider magnetic resonance imaging targeted biopsy an alternative to conventional systematic biopsy.

INTRODUCTION AND OBJECTIVES: When focal therapy (FT) is performed with sufficient intensity to eradicate cancer, accurate evaluation for the extent of significant cancer (SC) is essential to avoid undertreatment. By D0Amico risk category of prostate cancer (PC), we assessed the possibility of underdiagnosis by MRI and biopsy for: 1) extra-prostatic extension (EPE) at the ablation field; and 2) SC left in untreated area. We then verified the applicability of quadrant-based regional FT to intermediateand high-risk PC, compared with lowrisk PC. METHODS: We enrolled 203 PC patients in clinical stage T 2 on digital rectal examination who underwent multiparametric MRI, systematic 14-core biopsy, and radical prostatectomy. MRI interpretation followed the Prostate Imaging Reporting and Data System version 2. Cancer distribution was analyzed using a quadrant basis. Anterior and posterior prostatic quadrants were assessed through 4 anterior/lateral cores and 4 posterior/lateral cores, respectively. Additional MRI-targeted sampling was included in the assessment of Gleason score (GS). SC was defined as a lesion with volume 0.5 mL and/or GS 4+3 and/or EPE. We consider that the absence of EPE is a precondition for FT and that the absence of SC is prerequisite for the untreated area. Each prostate was examined for EPE using MRI, and each quadrant was then assessed for SC using MRI and 4 biopsy cores. RESULTS: In total, 35/109/59 men were classified as low-/ intermediate-/high-risk cases, respectively. In each risk groups, radiological EPE (rEPE) features on MRI were absent in 31/49/21 men (89/45/36% of each group). Among men without rEPE features in each group, EPE was pathologically absent in 30/47/19 men (97/96/90%) (p 1⁄4 1.00 and 0.56 in intermediateand high-risk groups, respectively, vs. the low-risk group). In men without rEPE features, SC was absent in 44/55/23 anterior quadrants (71/56/55%) and 46/55/22 posterior quadrants (74/56/52%). Negative predictive values of the combination of MRI and biopsy for SC were 95/96/100% in anterior quadrants (p 1⁄4 1.00 and 1.00 in intermediateand high-risk groups, respectively, vs. the low-risk group) and 94/98/89% in posterior quadrants (p 1⁄4 0.58 and 0.61). CONCLUSIONS: In intermediateand high-risk PC selected through MRI and biopsy, EPE is absent in 96% and 90% of men, respectively, and SC left in the untreated area is absent in 96-98% and 89-100% of quadrants, respectively, which suggests that FT is an option for intermediate-risk PC as well as low-risk PC. Although carefullyselected high-risk PC might also be a candidate for FT, further study using a larger cohort is needed.

We report how the incidence of primary and recurrent acute urinary retention changed in England between 1998 and 2003. In addition, we present data on changes with time in the use of prostatectomy after acute urinary retention and recurrent acute urinary retention.Data were extracted from the Hospital Episode Statistics database of the Department of Health in England. Patients were included in the study if an International Classification of Diseases, Tenth Revision code for acute urinary retention or an operative procedure code for transurethral prostate resection was present in any diagnosis or procedure fields of the Hospital Episode Statistics database. A total of 165,527 men were identified to have been hospitalized with acute urinary retention in the study period.The incidence of primary acute urinary retention was 3.06/1,000 men yearly. Acute urinary retention was spontaneous in 65.3% of cases. The incidence of acute urinary retention decreased from 3.17/1,000 men yearly in 1998 to 2.96/1,000 yearly in 2003. Surgical treatment following spontaneous acute urinary retention decreased 20% from 32% in 1998 to 26% in 2003. This trend coincided with a 20% increase in the rate of recurrent acute urinary retention.The slight decrease in the incidence of primary acute urinary retention suggests that the shift away from surgical treatment for benign prostatic hyperplasia has not resulted in an increase in acute urinary retention. The increase in recurrent acute urinary retention suggests that the observed decrease in surgery after acute urinary retention may have put more men at risk for acute urinary retention recurrence.

We performed a systematic review and critique of the literature of the relationship between hospital or surgeon volume and health outcomes in patients undergoing radical surgery for cancer of the bladder, kidney or prostate.Four electronic databases were searched to identify studies that describe the relationship between hospital or surgeon volume and health outcomes.All included studies were performed in North America. A total of 12 studies were found that related hospital volume to outcomes. For radical prostatectomy and cystectomy all 8 included studies showed improvement in at least 1 outcome measure with increasing volume and never deterioration. For nephrectomy the 4 included studies produced conflicting results. Four studies were found that related surgeon volume to outcomes. All radical prostatectomy and cystectomy studies showed that some outcomes were better with higher surgeon volume and never deterioration. We did not find any studies of the effect of surgeon volume on outcomes after nephrectomy. The 3 studies of the combined effect of hospital and surgeon volume on outcomes after radical prostatectomy or cystectomy suggest that high volume hospitals have better outcomes, in part because of the effect of surgeon volume and vice versa.Outcomes after radical prostatectomy and cystectomy are on average likely to be better if these procedures are performed by and at high volume providers. For radical nephrectomy the evidence is unclear. The impact of volume based policies (increasing volume to improve outcomes) depends on the extent to which "practice makes perfect" explains the observed results. Further studies should explicitly address selective referral and confounding as alternative explanations. Longitudinal studies should be performed to evaluate the impact of volume based policies.

Caroline Moore*, Veeru Kasivisvanathan, London, United Kingdom; Scott Eggener, Chicago, IL; Mark Emberton, London, United Kingdom; Jurgen Futterer, Nijemgen, Netherlands; Inderbir Gill, Los Angeles, CA; Robert Grubb, Washington, DC; Boris Hadashick, Heidelberg, Germany; Laurence Klotz, Toronto, Canada; Daniel Margolis, Leonard Marks, Los Angeles, CA; Jonathan Melamed, New York, NY; Aytekin Oto, Chicago, IL; Suzanne Palmer, Los Angeles, CA; Peter Pinto, Bethesda, MD; Phillipe Puech, Lille, France; Shonit Punwani, London, United Kingdom; Andrew Rosenkrantz, New York, NY; Ivo Schoots, Rotterdam, Netherlands; Richard Simon, Bethesda, MD; Samir Taneja, New York, NY; Baris Turkbey, Bethesda, MD; Osamu Ukimura, Los Angeles, CA; Jan van der Meulen, London, United Kingdom; Arnauld Villers, Lille, France; Yuji Watanabe, Kurashiki, Japan